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Signal transductionA number of experimental studies has documented that S-nitrosoglutathione (GSNO), the main
endogenous low-molecular-weight S-nitrosothiol, can exert modulatory effects on inﬂammatory
processes, thus supporting its potential employment in medicine for the treatment of important disease
conditions. At molecular level, GSNO effects have been shown to modulate the activity of a series of
transcription factors (notably NF-jB, AP-1, CREB and others) as well as other components of signal trans-
duction chains (e.g. IKK-b, caspase 1, calpain and others), resulting in the modulation of several cytokines
and chemokines expression (TNFa, IL-1b, IFN-c, IL-4, IL-8, RANTES, MCP-1 and others). Results reported
to date are however not univocal, and a single main mechanism of action for the observed anti-inﬂam-
matory effects of GSNO has not been identiﬁed. Conﬂicting observations can be explained by differences
among the various cell types studies as to the relative abundance of enzymes in charge of GSNO metab-
olism (GSNO reductase, c-glutamyltransferase, protein disulﬁde isomerase and others), as well as by vari-
ables associated with the individual experimental models employed. Altogether, anti-inﬂammatory
properties of GSNO seem however to prevail, and exploration of the therapeutic potential of GSNO and
analogues appears therefore warranted.
 2014 Published by Elsevier Inc.Introduction
S-Nitrosoglutathione (GSNO) is the endogenous S-nitrosylated
derivative of the major antioxidant glutathione (GSH). In the past
few years a large number of studies focused on GSNO properties –
i.e. synthesis, transport across cell membranes and biological
activities – and roles of GSNO as a store of nitric oxide (NO)1 or
as a component of NO-dependent signal transduction pathways
were proposed [1]. In this perspective, a number of recent reviewscomprehensively summarize the main ﬁndings in the ﬁeld (e.g.
[1–6]). As far as biological functions are concerned, one of the major
areas of interest is the role of GSNO as modulator of inﬂammatory
responses, with all the potential implications for GSNO-related ther-
apies. Therapeutic potential of GSNO has indeed been already shown
in several inﬂammation-related pathologic conditions, e.g. asthma
[7], cystic ﬁbrosis [8], undesired platelet aggregation and thrombo-
embolism [9] and brain ischemia–reperfusion [10].
Different in vitro and in vivo models have been employed to
investigate the modulatory role of GSNO on pro-inﬂammatory
cytokines expression, but conﬂicting results have been reported,
suggesting that several factors may inﬂuence the ﬁnal outcome
of GSNO treatment [11,12].
In the attempt to elucidate the mechanisms and the factors
involved, different compounds – such as organic nitrates (e.g.
glyceryl trinitrate), sodium nitroprusside (SNP), sydnonimines
(e.g. SIN-1), S-nitrosothiols (e.g. S-nitrosoglutathione, S-nitroso-
N-acetyl-DL-penicillamine) and NONOates (e.g. DETA-NONOate) –
have been employed. Unluckily these compounds are known to
decay with different mechanisms and with different kinetics
[13,14], thus making comparisons difﬁcult. An additional
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donor is its interaction with the tightly regulated endogenous pro-
duction of NO by nitric oxide synthases (NOS). Several studies
focused on the effects of inhibition/activation of NOS on cytokines
expression and inﬂammatory response [12,15,16].
Although with some discrepancies related to the analytical
method used [17,18], GSNO was found at nano- to low micromolar
concentrations in extracellular ﬂuids and tissues [17,19–21], and,
due to its nature of endogenous compound, it has been considered
an ‘‘attractive candidate’’ for GSNO-based therapies [8]. The aim of
the present review is to highlight some of the factors affecting the
experimental use of exogenous GSNO as modulator of inﬂamma-
tory cytokines expression and to discuss the inconsistencies
reported in literature.GSNO and inﬂammatory cytokines: lessons from in vitromodels
A selection of studies performed in vitrowith GSNO are summa-
rized in Table 1. The most commonly used models were by far
endothelial cells and peripheral blood mononuclear cells (PBMCs).
The majority of the works dealt with a selected group of cytokines
and chemokines, such as TNF-a, IL-1b, IL-6 and IL-8 [22–39], with
only a few studies focusing on different chemokines such as IP-10
or MCP-1 [29,31,40], IL-2 [40–42], M-CSF [43], IL-4 [32], TGF-b1
[44] and IL-17 [45].
The effects produced by GSNO are quite heterogenous, with
either a positive or a negative modulation of the same type of cyto-
kine (i.e. TNF-a, IL-6, IL-8). When results are compared on the basis
of cell types used, GSNO shows to exert an anti-inﬂammatory effect
on endothelial cells [23,25,28], whereas conﬂicting results were
obtained with respect to PBMCs and keratinocytes. The limited
number of studies, however, does not allow to outline any particu-
lar cell speciﬁcity. It is conceivable that GSNO may differentially
modulate cytokines expression in different cell types, also depend-
ing on both the tissue and the species (e.g. human, rat, mouse; [46]).
Another major issue of such studies is related to GSNO concentra-
tions used, ranging from as low as <10 micromolar up to P1 mM,
i.e. concentrations even a hundred-fold higher than those usually
detected in biological ﬂuids. As a consequence, these data could
help us elucidate the effects and the cellular targets of pharmacolog-
ical – rather than physiological – GSNO concentrations [47].
In a small number of studies [22,35,38,39,43,44], the effects
produced by exogenously added GSNO were also compared with
those obtained by modulating endogenous NO production, mainly
through NOS induction or inhibition. However a speciﬁc evaluation
of endogenous levels of GSNO upon NOS modulation was not per-
formed. In a study on a human mast cell line, the effects produced
by eNOS induction upon IFN-c treatment were mimicked by NO
donors [35], and similar results were obtained in a human prostate
cancer cell line transfected with iNOS [44]. NOS inhibitors such as
NG-amino-L-homoarginine (NAHA) [22], NG-methyl-L-arginine
(L-NMA) [43,44], NG-monomethyl-L-arginine (L-NMMA) [38] or
NG-nitro-L-arginine methyl ester (L-NAME) [35] were also used.
In other studies on murine macrophages, GSNO inhibited IL-1b
secretion, whereas iNOS silencing by siRNA, its inhibition by
L-NMMA [38] or the use of macrophage from mice lacking iNOS
(iNos/) produced opposite effects [39].
Nevertheless it is conceivable that several factors – other than
GSNO concentration – are likely to contribute to the ﬁnal outcome
of GSNO treatments.GSNO decomposition
The half-life of the various S-nitrosothiols (SNOs) currently used
varies dramatically depending on the biological system in whichthey are used [1]. S-nitrosothiols are subject to several mecha-
nisms of decomposition, including S/N bond homolysis, photolytic
S/N bond cleavage, metal ion-catalyzed decomposition, and
hydrolysis [1]. As compared to other S-nitrosothiols, GSNO is quite
stable – nevertheless, different non-enzymatic as well as
enzymatic pathways were shown to promote GSNO degradation.
From a chemical point of view, GSNO can react with other bio-
logical molecules such as thiols (e.g. GSH, Cys), ascorbate, iron and
copper ions. Nevertheless, in the cellular context the predominant
reaction is supposed to be the enzymatic reduction of GSNO (see
[1] for references). However it cannot be excluded that different
culture conditions/incubation mixtures may inﬂuence GSNO sta-
bility or differentially address its ﬁnal effects after an enzymatic
reduction [48].
Different enzymes were shown to promote GSNO decomposi-
tion (Fig. 1). GSNO reductase (GSNOR; also known as alcohol
dehydrogenase class III or glutathione-dependent formaldehyde
dehydrogenase) is a NADH-dependent member of the alcohol
dehydrogenase family. Studies in vitro demonstrated that GSNO
is reduced by GSNOR using NADH as a cofactor to produce an inter-
mediate (GSNHOH) which can either react with GSH to produce
glutathione disulﬁde (GSSG) and hydroxylamine (NH2OH) or rear-
range to glutathione sulﬁnamide. Subsequently glutathione sulﬁn-
amide can spontaneously hydrolyze to produce glutathione sulﬁnic
acid (GSO2H) and ammonia (NH3) (see Fig. 1) [49–51]. Several
studies have established an important role for GSNOR in signal
transduction by nitric oxide and protection against cytostatic or
cytotoxic effects resulting from pathophysiological levels of
protein S-nitrosylation [52,53]. It has been proposed that the
homeostasis of endogenous NO/GSNO/SNO resulting from double
gate-controlled modulation by synthases (NOS) and GSNOR might
be critical in immune responses [4]. Indeed GSNOR is the only
enzyme that has been demonstrated to regulate S-nitrosothiols
levels in vivo, and connections between GSNOR activity and human
disease have been suggested (see [1,5] for references). In this per-
spective, GSNOR has been proposed as a target for therapy in some
pathological conditions such as lung and cardiovascular disorders,
asthma and other inﬂammatory diseases [1].
c-Glutamyltranspeptidase (GGT) is a plasma membrane
enzyme that extracellularly hydrolizes GSNO to the less stable
S-nitroso-cysteinylglycine (CGSNO) which rapidly releases NO in
presence of trace metal ions [48,54]. It was suggested that further
cleavage of CGSNO by a peptidase or transnitrosylation of a
L-cysteine (L-Cys) residue can eventually produce S-nitroso-L-
cysteine (CysNO; Fig. 1) [55,56]. CysNO can rapidly transfer SNO
moiety into cells through the L-amino acid transporter system
(L-AT) located on the plasma membrane [2,5]. CGSNO too could
readily be imported into the cell by a dipeptide permease, a mem-
ber of the ABC transporter family – as suggested by early studies on
Salmonella typhimurium [57]. Nevertheless, other studies on RAW
264.7 cells demonstrated that extracellular GSNO can mediate
intracellular S-nitrosothiol formation only when co-incubated with
speciﬁc low molecular weight thiols [56]. In particular, incubations
with GSNO and L-cysteine, L-cystine or D/L-homocysteine are able
to increase intracellular S-nitrosothiol formation, whereas incuba-
tions with GSNO and L-cysteinyl-glycine do not [56]. Nevertheless
it can be envisaged that by cleaving GSNO, GGT may play a role in
facilitating SNO uptake and S-nitrosylation of intracellular proteins
[2,48]. In this regard, it was demonstrated that GSNO-induced Akt
kinase activity and the subsequent downstream HIF-1a stabiliza-
tion are blocked by acivicin, a GGT inhibitor [58]. Similarly, acivicin
prevents the effects of GSNO on 5-lipoxygenase expression in A549
cell line [59], whereas a GGT dependent GSNO catabolism differen-
tially regulates IL-8 expression in IB3-1 cell line [37]. Interestingly,
GGT expression levels vary considerably among cells types [60]
and it may increase upon cell activation [42,61,62].
Table 1
GSNO effects on cytokines production in in vitro models.
Cellular model Stimulus GSNO
concentration
Cytokines
modulated*
Other factors
modulated
Pathways
studied
References
Human PBMCs, T cells PHA 25 lM - IL-2 ;; DNA synthesis " cGMP [41]
- IL2R
Human melanoma cell line G361 – 100–300 lM "" IL-8 – " NF-jB, [22]
" NF-IL-6
- AP-1
HSVEC IL-1a 30 lM–1 mM ;; IL-6 ; VCAM-1 ; NF-jB [23]
IL-1b ; IL-8 ; ICAM-1 cGMP-ind.
IL-4 ; E-selectin
TNF-a
LPS
HSVEC TNFa oxLDL 200–500 lM ;; M-CSF – ; NF-jB [43,106]
" IjBa
 AP-1
- GATA2
- GATA3
cGMP-ind.
Human neutrophils LPS 0–2 mM "" IL-8 - Cell viability cGMP-ind. [24]
Human T and B cell lymphoma; peripheral blood T
cells
– 50 lM–1 mM " IL-2 ;; DNA synthesis – [42]
Anti-human
CD3
- IL-2
Human endothelial cell line ECV304 TNF-a 100 lM–1 mM ;; IL-8 ;; Migration of
neutrophils
; NF-jB [25]
" IjBa
KB and HaCaT human keratinocyte cell lines IL-1b 100–300 lM " IL-8 – – [26]
Human monocytic U937 cells PMA 500 lM " TNF-a – ; Sp1 [27]
cAMP-dep.
Human endothelial cell line ECV304 TNF-a 250 lM–1 mM ; IL-8 – ; AP-1 [28]
; JNK
Primary human keratinocytes IFN-c 100 lM–
2.5 mM
;; IP-10 ; ICAM-1 ; NF-jB [29]
TNF-a ;; RANTES ; STAT-1
Serum-free
medium
; MCP-1 - AP-1
- IL-8
Human monocytic U937 cells – 300–500 lM "" IL-8 – Role of: [30]
OH
p38
NF-jB
PI3K
Human monocyte-derived DCs LPS 0–2.5 mM "" IFN-c ; CD86 – [31]
CD40 ligand ;; IL-5 - CD80
;; IL-10 - CD83
" TNF-a - MHC class I and II
;; IL-12 p40
- IL-12 p70
; IP-10
; RANTES
- IL-8
Human PBMCs PHA 250 lM ;;/" IL-2 ;; Cell proliferation – [40]
IL-2 ; IL-13 - CD3
; IFN-c - CD25
- IL-4
- Lymphotactin
- RANTES
- IP-10
- MIP-1a
- MIP-1b
- MCP-1
- IL-8
Rat RBL-2H3 and mouse BMMC mast cells IgE/Ag 125–500 lM ;; IL-4 ; Degranulation ; AP-1 [32]
;; IL-6 ; PLCc1
;;TNF-a ; NF-AT
- NF-jB
- CREB
- MAPKs
Human monocytes TNF-a 0.0005–1 lM "" TNF-a "" IRAK-M – [33]
- Cell viability
Human THP-1 cells and primary human monocytes LPS 50–500 lM "" IL-8 – " p38
- AP-1
- NF-IL-6
- NF-kB
- Oct-1
cAMP-ind.
cGMP-ind.
[34]
" TNF-a cAMP-dep.
cGMP-ind.
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Table 1 (continued)
Cellular model Stimulus GSNO
concentration
Cytokines
modulated*
Other factors
modulated
Pathways
studied
References
Human mast cell line HMC1 IFN-c and PMA 100 lM ; IL-8 – – [35]
; CCL1
Human prostate cancer cells PC-3MM2, LNCaP and
DU145
Serum-free
media
50 lM-1 mM ; TGF-b1 – – [44]
Mouse CD3 positive T cells CD3/28
antibodies
1–400 lM ;; IL-17 – ; STAT3 [45]
- IL-4 ; RORc
- STAT4
- STAT6
- T-bet
- GATA3
Human PBMCs – <10 lM " IL-6 – " NF-jB
cGMP-dep.
[36]
– >100 lM ; IL-6 – ; NF-jB
cGMP-dep.
Human bronchial epithelium IB3–1cells LPS 300 lM " IL-8 " Cell proliferation  NF-jB
" p38
- ERK1/2
- JNK
[37]
LPS + GGT ;; IL-8 ; Cell proliferation ; NF-jB
; ERK1/2
" p38
- JNK
Murine peritoneal macrophages; human THP-1 cells;
human PBMCs
LPS 100 lM–1 mM ;; IL-1b ;; Caspase-1 ; NLRP3 [38]
ATP - IL-6
Nigericin - TNF-a
MSU
Mouse macrophages Pam3CSK4 125–500 lM ;; IL-1b ;; Caspase-1 ; NLRP3 [39]
- TNF-a cGMP-ind.
Abbreviations and symbols used: cAMP-dep. = effects observed are cAMP dependent; cGMP-ind. = effects observed are not cGMP dependent; DCs = dendritic cells;
GGT = gamma-glutamyltransferase; HSVEC = human saphenous vein endothelial cells; MSU = monosodium urate crystals; PBMCs = peripheral blood mononuclear cells;
PHA = phytohemagglutinin; PI3K = phosphoinositide 3-kinase; PMA = phorbol 12-myristate 13-acetate; PLCc1 = phospholipase Cc1; ":‘‘increase of’’; ;:‘‘decrease of’’;
"":‘‘increaseP 100%’’; ;;:‘‘decreaseP 50%’’; -:‘‘no effects on’’ : ‘‘slight variation’’.
* Data reported are referred to modulation of mRNA expression, protein or both.
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bonyl reductase 1 (CBR1) and the thioredoxin system. The former
shows some similarities of reaction products and stoichiometry
with GSNOR (see Fig. 1) [63,64]. The latter is one of the major play-
ers in the reduction of low-molecular weight and protein S-nitroso-
thiols and is involved in both denitrosylation and transnitrosylation
reactions. The proposedmechanism implies that the reaction occurs
through transnitrosylation of thioredoxin (Trx) and release of GSH.
Then nitroxyl (HNO) is released and oxidized Trx is ﬁnally reduced
by thioredoxin reductase (TrxR) and NADPH (Fig. 1) [65].
In addition, other enzymes such as cell surface protein disulﬁde
isomerase (PDI) [66–68], copper- and zinc-containing superoxide
dismutase (CuZnSOD) [69,70], xanthine oxidase [71,72] and gluta-
thione peroxidase 1 (GPx1) [73] have been suggested to affect
GSNO metabolism/degradation [1] (Fig. 1). The catalytic mecha-
nism proposed for PDI involves a nitroxyl disulﬁde intermediate
which, after undergoing a one-electron oxidation, decomposes to
yield NO plus dithiyl radical. The ﬁnal product after one enzymatic
turnover is an oxidized protein active site and NO [68]. CuZnSOD
was suggested to catalyze the reductive cleavage of GSNO. The
mechanism involves GSH and the redox turnover of copper in
CuZnSOD, with the latter serving as a highly efﬁcient catalyst of
GSNO breakdown [70]. GSH would reduce enzyme associated
Cu2+ to Cu1+ which in turn would mediate the reductive decompo-
sition of GSNO. CuZnSOD – but not MnSOD [69] - would thus func-
tion in vitro as a NO S-transferase, catalyzing NO transfer from
GSNO to protein targets [70]. Also xanthine oxidase (XO) – in the
presence of purine (hypoxanthine, xanthine) substrates – was
demonstrated to induce GSNO decomposition. The proposed
mechanism involves a superoxide anion-dependent reduction of
GSNO to yield NO, which in turn reacts with a second superoxide
anion molecule to yield peroxynitrite [71,72]. Finally GSNOdecomposition by selenium-containing GPx1 was also described.
The proposed mechanism is based on the diselenides-catalyzed
formation of NO from S-nitrosothiols in the presence of thiols.
The diselenide (R0Se-SeR0) reacts with the free thiol (RSH) to
produce the selenosulﬁde (RS-SeR0) and the selenol (R0SeH). The
selenol generated reacts with RS-NO to release NO and a disulﬁde
(RS-SR) [73].
Against this background, it is conceivable that different cell
types may express different levels of the above mentioned
enzymes, and that experimental conditions may modify such
expression. For instance, it is known that (a) GGT is induced upon
exposure of cells to oxidative stress or cytokines (see [62] for ref-
erences) and that (b) different levels of GGT can be detected in
incubation media depending on the ﬁnal FCS concentrations
added.
GSNO concentrations, incubation times, co-administration of other
agents
Part of the inconsistencies observed upon GSNO treatments
likely just depend on the activation status of cells, i.e. the presence
of other stimulating/inhibiting conditions or compounds, such as
LPS, TNF-a and IFN-c (Table 1). The employment of serum-free
media [29,44,74] is also a critical point in many studies, as cellular
susceptibility towards NO largely dependent on the pre-activating
stimuli [75]. The absence of serum may in fact produce a cell
‘‘priming’’ due to starvation [76]. On the other hand, the presence
of serum during incubations may also have consequences due both
to S-nitrosothiols reaction with serum protein thiols [2] and to the
presence of GSNO degrading enzymes (e.g. GGT).
Factors such as GSNO concentration and length of incubation
are also likely to inﬂuence signiﬁcantly the ﬁnal outcome. A
Fig. 1. Proposed mechanisms for the enzymatic decomposition of GSNO. Schematic
representation of GSNO decomposition by (1) GSNO reductase (GSNOR) [49,148],
(2) c-glutamyltranspeptidase (GGT) [48,149], (3) carbonyl reductase 1 (CBR1) [63],
(4) thioredoxin system (Trx/TrxR) [65,150], (5) protein disulﬁde isomerase (PDI)
[68], (6) copper- and zinc-containing superoxide dismutase (CuZnSOD) [70], (7)
xanthine oxidase (XO) [71,72] and (8) glutathione peroxidase 1 (GPx1) [73]. See text
for more details.
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for different NO-donors [77,78], including GSNO. Low, ‘‘physiolog-
ical’’ GSNO concentrations (<10 lM) were found to increase the
nuclear speciﬁcity proteins (Sp)3-dependent transcription, whileinhibiting Sp1 binding to DNA in A549 cells. Conversely, higher
GSNO concentrations (10–100 lM, as those associated with
inﬂammation and nitrosative stress) promoted opposite effects
[47]. It was proposed that physiological levels of GSNO may pro-
mote physiological homoeostasis, whereas nitrosative stress levels
may signal a change from the expression of housekeeping genes to
the expression of stress-response genes [47]. At variance, Sp1/Sp3-
dependent expression of 5-lipoxygenase (5-LO) was shown to be
increased at low (<1 lM) and inhibited at higher (>5 lM) GSNO
concentrations, respectively [59]. Similarly, NF-jB activation and
IL-6 expression were promoted at lower (<10 lM) and decreased
at higher (>100 lM) GSNO concentrations [36]. A biphasic effect
was also demonstrated for HIF-1a activation/accumulation,
100 lMGSNO being able to attenuate CoCl2-induced HIF-1a stabil-
ization and 1 mM GSNO being ineffective [79]. Finally, an alleged
‘‘triphasic’’ GSNO-dependent PPARc activation – remarkable at
100–200 lM but virtually absent at doses lower than 50 lM or
higher than 500 lM – was also described [80].
It is likely that these quite paradoxical concentration-dependent
effects might reﬂect the different sensitivity of cellular targets to
GSNO. This behavior is not a speciﬁc property of GSNO: similar
biphasic responses are known to be produced, e.g. by redox regula-
tion of factors such as NF-jB. Indeed, the nuclear translocation of
NF-jB requires an oxidative environment – capable of favouring
the degradation of IjB – whereas its binding to the DNA requires
a reducing environment. High levels of oxidative stress may impair
the nuclear redox status, thus hampering NF-jB DNA binding
[81,82]. Notably, part of the targets known to be modulated by
S-nitrosothiols is represented by factors involved in cell signaling,
including ubiquitylation, thus supporting its broad pleiotropic
inﬂuence on protein post-translational modiﬁcation [83]. Interest-
ingly, the enhanced Sp3–DNA binding in the presence of physiolog-
ical concentrations of GSNO is associated with increased Sp3
expression, which in turn may partially result from the inhibition
of Sp3 ubiquitination and proteosomal degradation. At levels of
GSNO associated with nitrosative stress, Sp3 binding is shut off, at
least partially through inhibition of Sp3 expression [47].
Despite the growing number of reports outlining novel protein
targets for S-nitrosothiols, there is a limited number of studies
focusing on the levels of the S-nitroso species found in cells or tis-
sues under physiological or pathological conditions [84].
As stated above, the greater part of published in vitro studies –
including those reported in Table 1 – employed GSNO concentra-
tions that are higher than those detectable in vivo in resting
conditions [8,11]. As already mentioned, it cannot be excluded that
such GSNO concentrations are reached under pathological or phar-
macological conditions [47].
Another critical point is certainly the timing of GSNO adminis-
tration – relative to that of other compounds. In a study on human
PBMCs, preincubation of cells with GSNO for 48 h before PHA
exposure strongly inhibited IL-2 release, whereas simultaneous
addition of both compounds signiﬁcantly enhanced it [40]. Simi-
larly, extended pre-incubation times (24–48 h) with a NO donor
were shown to be required in mast cells for inhibition of
IgE/Ag-induced cytokines expression and degranulation [32,85,86].
Finally, experimental conditions used may also dramatically
inﬂuence the ﬁnal outcome. In early papers (e.g. [87]) GSNO was
used in combination with superoxide dismutase added as a ‘‘pro-
tecting’’ agent, i.e. to prevent superoxide from binding to and inac-
tivating NO. However, CuZnSOD was also proposed to function
in vitro as an NO S-transferase, catalyzing NO transfer from GSNO
to protein targets [70].
Lastly, additional variability can derive from the oxygen con-
centration during incubations. GSNO has in fact been reported to
promote HIF-1a stabilization under normoxia [88,89] while inhib-
iting it under hypoxia (see below for more details) [90,91].
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The mechanisms of GSNO formation in vitro, have been studied
in some detail, and some explanations have been proposed, e.g.
direct reaction of NO/nitrosylating species with GSH or formation
of protein/lowmolecular weight S-nitrosothiols followed by subse-
quent transnitrosation to GSH [1,92]. Nevertheless, our knowledge
of the mechanisms of S-nitrosothiol formation in vivo is still
incomplete [84]. Similarly, the mechanisms by which GSNO can
inﬂuence cellular responses have also been extensively studied.
In a recent review, Broniowska and colleagues [1] outline the fact
that most of the studies employing GSNO were interpreted accord-
ing to the wrong assumption that GSNOmainly works by liberating
NO. Actually several factors – as summarized above – may pro-
foundly affect the speciﬁc mechanism of GSNO decay. Moreover
it is worth remarking that biochemical changes occurring after cell
exposure to S-nitrosothiols (with respect to thiol chemistry) are
different from those observed upon NO exposure [56].
A ﬁrst issue is related to GSNO uptake. As stated above, it was
demonstrated that GSNO itself cannot enter directly into cells
and that the predominant mechanism involved requires the trans-
fer of the nitroso group from GSNO to the thiol group of extracel-
lular L-Cys. The CysNO thus formed was shown to be readily
transported into cells by means of the L-amino acid transporter
system (L-AT), and to S-nitrosylate other low molecular weight
thiols (mainly GSH) or protein thiols intracellularly [1,56]. It is con-
ceivable that the redox state of the cell may inﬂuence extracellular
L-Cys availability, which in turn is supposed to derive from extra-
cellular cystine through the sequence cystine uptake–intracellular
reduction–cysteine release [56]. Likewise, speciﬁc experimental con-
ditions, such as the composition/integration of incubation media,
can substantially inﬂuence L-Cys availability [5,56,93,94].
Other mechanisms involving the delivery of NO or its oxidation
products have been described [1,84], and it is interesting to note
that this route is also subject to differential modulation. For
instance, it was demonstrated that cholesterol content in mem-
branes contributes to the spatial heterogeneity of NO diffusion
and signalling, as the diffusion rate of NO across membranes is
inversely related to the cholesterol content [95].
A second issue is how GSNO can modulate cellular responses. It
was observed that S-nitrosothiols may mimic many of the
downstream effects of NO, but through potentially disparate intra-
cellular mechanisms [56]. Moreover the effects of exogenous
S-nitrosothiols on intracellular S-nitrosylation have little to share
with the cell biology of NO [2]. As regard GSNO in particular, two
additional mechanisms of action were proposed, i.e. protein
S-nitrosylation and protein S-glutathionylation, besides canonical
NO-dependent pathways [1,84,96].
Protein S-nitrosylation
S-nitrosylation – the covalent attachment of NO to the sulfur
moiety of cysteine – is a post-translational, redox sensitive, revers-
ible modiﬁcation. It is known that its target cysteine residues are
highly tissue- and context-speciﬁc, and that their S-nitrosylation
is dynamically regulated both in synthesis and degradation [1,5].
Probably the most important reaction of a S-nitrosothiol inside a
cell or in a biological ﬂuid is transnitrosylation, i.e. the reversible
transfer of the S-nitroso functional group to a receiving thiolate
compound [84]. A large number of proteins has been shown to
undergo S-nitrosylation and among them some trascriptional reg-
ulators and upstream intermediates involved in cells signaling [6].
S-nitrosylation leads to changes in protein activity, protein–protein
interactions or subcellular location of target proteins, and is in
many ways analogous to phosphorylation [3]. The picture is
further complicated by the fact that modulation of cell signals by
S-nitrosylation often affects factors involved in other majormechanisms of post-translational modiﬁcation, such as phosphor-
ylation, acetylation or ubiquitination [83].
S-nitrosylation is primarily regulated enzymatically, with NOSs
and additional enzymes (e.g. GSNOR, thioredoxin) capable of per-
forming S-nitrosylation and denitrosylation reactions [3,96,97].
S-nitrosylation thus meets the requirements of a regulatory post-
translational modiﬁcation, including speciﬁcity, reversibility and
enzymatic control [15], although – at variance with phosphoryla-
tion – is not strictly dependent on enzymes for its formation and
breakage [96]. Exposure of cells to exogenous S-nitrosothiols is
therefore likely to interfere with this tightly regulated mechanism.
As reported in Table 1, major transcription factors such as
NF-jB, AP-1 and HIF-1a – involved in cytokines expression – were
shown to be modulated by GSNO. A recent review by Sha and
Marshall [6] exhaustively summarized how S-nitrosylation regu-
lates gene transcription as well as the multiple targets involved.
Nuclear factor jB (NF-jB) is a transcriptional factor regulated
through complex interactions of IjB family of inhibitory proteins
and IjB kinases-mediated phosphorylation events. Studies on
NF-jB S-nitrosylation were performed with different NO-donors
such as SNP, SNAP, or S-nitrosocysteine in both cellular and cell-
free systems. DNA binding of NF-jB was shown to be inhibited
by S-nitrosylation of a speciﬁc cysteine on the p50 monomer
[98–100] as well as by S-nitrosylation [101] or Tyr-nitrosylation
[102] on the p65 monomer. As far as GSNO is concerned, in endo-
thelial cells TNF-a mediated activation of NF-jB was shown to
involve denitrosylation of p65, while GSNO mediated inhibition
was associated with S-nitrosylation of the same monomer [103].
This suggests that the net activation of NF-jB in endothelial cells
during inﬂammation could depend on a balance between stimula-
tory and inhibitory factors, and that constitutive NO production
may play a role in tonically inhibiting NF-jB activation under basal
conditions [43]. Others have shown that IKKb – the catalytic
subunit of IKK complex required for NF-jB activation – may also
undergo S-nitrosylation upon exposure to GSNO and L-Cys, thus
resulting in NF-jB inhibition. Again, TNF-a stimulation induced a
rapid denitrosylation and activation of IKK [104]. Conversely, in a
study with an ovalbumin model of allergic airway disease in mice,
GSNO induced S-nitrosylation of NF-jB p65 but did not affect IKKb
[105]. In endothelial cells and neutrophils, GSNO was demon-
strated to stabilize the NF-jB inhibitory protein IjB-a by
preventing its degradation and/or by increasing its expression
[25,106–108]. On the contrary, other studies showed no involve-
ment of NF-jB upon GSNO exposure [32,34], whereas its activation
was instead shown in a small number of cases [22,36,80]. An indi-
rect effect of GSNO on cytokines expression can be mediated
through the NF-jB dependent expression of cyclooxygenase-2
(Cox-2) and the consequent prostaglandin biosynthesis, although
conﬂicting reports also exist on this point [80,109].
Activating protein (AP)-1 is a heterodimeric transcription factor
belonging to the basic domain leucine zipper (bZIP) family, consist-
ing – in its most active form – of the two subunits Fos and Jun. Con-
ﬂicting results are reported as regard GSNO effects on DNA binding
of AP-1, oscillating between inhibition [28,32,106] and induction
[80,110]. The mechanisms proposed are either dependent on cGMP
[110] or based on down-regulation of c-Jun N-terminal kinase
(JNK) [28]. However, NO-donors such as SNP or SIN-1 were shown
to promote direct S-nitrosylation of Jun and Fos, thus inhibiting
DNA binding of AP-1 [111,112].
Hypoxia-inducible factor-1 (HIF-1), the transcription factor
regulating the expression of several genes involved in hypoxic
tolerance and inﬂammation, is a heterodimer composed of two
subunits: the regulatory subunit HIF-1a and the constitutively
expressed HIF-1b. In hypoxia, HIF-1a is stabilized through
decreased activity of prolyl hydroxylases that target the protein
for degradation. Under normoxia, exposure to GSNO can result in
Fig. 2. Schematic representation of targets modulated by GSNO dependent
reactions. GSNO has been shown to modulate inﬂammatory processes by affecting
the activation status of a series of transcription factors and other components of
signal transduction chains. Results to date are however not univocal and part of
these inconsistencies can be explained by differences among cell types as to the
relative abundance of enzymes active in GSNO metabolism, as well as by variation
of conditions in different experimental models.
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binding) through distinct mechanisms, i.e. a phosphatidylinositol
30-kinase (PI3K)–Akt-dependent pathway [89,113] or an increased
expression of both HIF-1a and HIF-1b [88], possibly depending on
S-nitrosylation, which is in fact known to increase HIF-1 activity by
modifying HIF-1a at two distinct cysteine residues [114,115].
GSNO also prevents HIF-1a degradation by inhibiting its ubiquiti-
nation. Indeed, in human embryonic kidney cells under normoxic
conditions, GSNO was shown to inhibit HIF-1a prolyl hydroxylase
(PHD) activity in a dose-dependent fashion, thus inhibiting the
subsequent interaction of HIF-1a with von Hippel Lindau protein
(pVHL) [116]. Conversely, other authors demonstrated that GSNO
can promote HIF-1a inhibition under hypoxia, possibly through
PHD activation [90,117,118]. The mechanism modulating PHD
activity is supposed to be driven by NO interaction with a ferrous
iron ligand located within the PHD active site [116].
Other signal transduction pathways have been shown to be
affected by GSNO. In a study on U937 human myelomonocytic
cells, it has been demonstrated that also Sp1 and Sp3 transcription
factors are intracellular targets of GSNO [27]. GSNO concentrations
<10 lM were shown to increase Sp3 and to inhibit Sp1 DNA bind-
ing, respectively. On the other hand, higher GSNO levels resulted in
a complete reversal of the observed effects [47]. It is conceivable
that these might be mediated by the S-nitrosylation of cysteine
residues in Sp3 and Sp1 speciﬁc domains [119].
Components belonging to the Ras and JNK pathways were also
shown to be modulated. GSNO can S-nitrosylate Ras [120] with
possible consequences on downstream pathways including ERK1/
2, Jak-STAT, and phosphoinositide 3-kinase (PI3K)–Akt. GSNO
was indeed shown to modulate the activity of PI3K–Akt and PTEN
[58,113,121]. Other targets of GSNO are mitogen-activated protein
kinase (MAPKs), JNK [28,122], ERK1/2 [37,80] and p38 [34,37]. The
latter is implicated in the stabilization of mRNAs containing AU-
rich elements in their 30-untranslated regions, as is the case with
major cytokines TNFa, IL-1b, IL-6 and IL-8 [123].
Other targets of GSNO modulation are elements operating
upstream of NF-jB, AP-1 or MAPKs. Elements in Toll-like receptors
(TLRs) and NOD-like receptors (NLRs) signaling were also shown to
be modulated by S-nitrosylation. TLRs are the central innate
immune sensors for a broad array of pathogen- and damage-
associated molecular patterns (PAMPs; DAMPs) and upon ligand
binding they initiate signaling cascades leading to the activation
of transcription factors such as AP-1, NF-jB and interferon regula-
tory factors (IRFs) [124]. With the exception of TLR3, all TLRs uti-
lize a MyD88-dependent pathway resulting in the production of
TNF-a, IL-1, IL-6 and other cytokines dependent on NF-jB; they
also trigger MAPKs cascades that lead to activation of AP-1 and
cyclic AMP response element-binding protein (CREB). MyD88 is
an adaptor protein recruited upon receptors activation. It was
observed that a speciﬁc S-nitrosylation within MyD88 Toll/inter-
leukin-1 receptor homology (TIR) domain resulted in a slight
reduction of NF-jB activation [125].
Several cytokines that play important functions during develop-
ment, tissue modeling and/or immune responses are known to be
subject to posttranslational processing and control. Activation of
TLRs pathway leads to the transcription of the pro-IL-1b gene,
but the subsequent processing of the precursor peptide into its
active form is mediated by multi-protein complexes termed
‘inﬂammasomes’. These hetero-oligomeric structures consist of
the IL-1b processing enzyme caspase-1, the adapter protein ASC,
and a sensor protein of the NLR (NOD-like receptor) or ALR
(AIM2-like receptor) families. Among others, the NLRP3 inﬂamma-
some is a multi-protein complex that triggers the maturation of the
pro-inﬂammatory cytokines IL-1b and IL-18 [126]. Interestingly, it
was demonstrated that GSNO dramatically inhibited IL-1b secre-
tion from murine peritoneal macrophages in a dose-dependentmanner, whereas IL-6 or TNF-a secretion was not affected [38].
Similarly, in a model ofMycobacterium tuberculosis-infected mouse
macrophages, GSNO and SNAP were shown to inhibit the process-
ing and release of IL-1b (but not TNFa) as efﬁciently as IFN-c [39].
Authors demonstrated that NO can promote S-nitrosylation of both
NLRP3 and caspase-1, but only NLRP3 S-nitrosylation appears to
inhibit the assembly of the NLRP3 inﬂammasome and IL-1b release
[39]. These pieces of evidence were paralleled by the observation
that endogenous NO derived from iNOS also negatively regulated
NLRP3 inﬂammasome activation [38,39].
In this complex regulatory mechanism, factors like CREB and
caspase 1 may also be modulated by S-nitrosylation [6,38,39,127].
Another route through which GSNO may modulate cytokines
expression involves S-nitrosylation of cysteine protease calpain.
Calpain was shown to be inhibited by S-nitrosylation of its active
site thiol group, resulting in a down-regulation of mast cells adhe-
sion to ﬁbronectin [128]. Interestingly, calpain inhibition was also
demonstrated to downregulate Th1/Th17 inﬂammatory cytokines
and mRNA in PBMCs of multiple sclerosis patients [129].
Table 2
GSNO effects on inﬂammation in in vivo models.
Model Disease GSNO treatment GSNO treatment effects References
Rat Chronic cerebral hypoperfusion 50 lg/kg/day
2 months
"" Learning and memory (day
4–6)
Brain tissue
; ICAM-1/VCAM-1
; amyloid-b (Ab)
Brain Endothelial cell culture
; NF-jB, ; STAT3
; ICAM-1, ; VCAM-1
Rat primary neurone cell
; b-secretase activity
[137]
Rat Focal cerebral ischemia 1 mg/kg body weight jugular vein cannulation at the time of
reperfusion
;; infarction area
" cerebral blood ﬂow
Brain tissue
; TNF-a, ;IL-1b
; iNOS
; microglia/macrophage (ED1,
CD11-b)
; leukocyte function-
associated antigen-1
; intercellular adhesion
molecule-1
;; caspase-3
Rat primary astrocytes cell &
microglial cell line BV2
; NF-jB
; iNOS
[138]
Rat Controlled cortical impact (CCI) 50 lg/kg body weight orally 2 h following CCI, and repeated daily "" motor function (14 days)
" neurological score (6 days)
"" sensory dysfunction
(>7 days)
Brain tissue
; ICAM-1
; microglia/macrophage (ED1)
; MMP-9
; iNOS
; apoptosis
; blood brain barrier leakage
and edema
" ZO-1, " occludin
[139]
Rat Controlled cortical impact (CCI) 50 lg/kg body weight orally 2 h following CCI, and repeated daily Brain tissue
; inﬂammatory inﬁltration
;; ICAM-1 mRNA
; 3-nitrotyrosine (3-NT), ; 4-
HNE
; blood brain barrier leakage
and edema
;; brain infarction area
; loss of myelin and damage to
axons
" total and reduced GSH
plasma
; ONOO, ; TBARS, ; 3-NT
[140]
Mice Experimental autoimmune
encephalomyelitis (EAE)
0.5 or 1 mg/kg, oral administration daily from day 0 (prophylaxis) or
when mice had visible EAE symptoms
; EAE symptoms
Spinal cord
;; CD4+ inﬁltration
Treated animals splenocytes
;; IL-17
- IFN-c and IL4 production
[45]
Mice Cerebral Malaria 3.5, 0.35, 0.035 mg/mice, IP, twice a day from day 0 to day 8 ; parasite growth (3.5 mg/
mice)
;; leukocytes in brain vessels
;; brain haemorrhages
(3.5 mg/mice)
" GSH
[141]
Rat Lumbar spinal stenosis 50 lg/kg body weight 1 h after the injury, and daily thereafter. ; locomotor dysfunction
" pain threshold
Spinal cord
; demyelination
[142]
(continued on next page)
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Table 2 (continued)
Model Disease GSNO treatment GSNO treatment effects References
;; cellular inﬁltration
; apoptosis
nerve ﬁbers
" endothelial VEGF
Mice Ovalbumin-induced Allergic
airway disease
500 nmol oropharyngeal administration 30 min before OVA
challenge
Lung tissue
; HIF-1 activation by hypoxia
; NF-jB activation
" S-nitrosylation of p65
- increased cellular inﬁltration
- increased mRNA of IL-13,
MUC5ac, GOB5, iNOS
Bronchoalveolar lavage
- increased cell counts
- increased protein levels
Plasma
- increased OVA-speciﬁc IgE
[105]
Mice Experimental autoimmune
uveitis
1 mg/kg/day 14 days Retina
" retinal protection
; mRNA for TNFa,
;; mRNA for IL-1b, IFN-c
;; mRNA for IL-10
- IL-4, - IL-6
Splenocytes
; T-cell proliferation
;; secretion of TNF-a, ;IFN-c
;; secretion of IL-10.
[143]
Mice Conditional ablation of enteric
glia cells
10 mg/kg/day, intraperitoneal administration In vivo
; intestinal permeability
Intestinal tissue
;; TNF-a mRNA
Caco-2 cell line
" ZO-1 expression
" F-actin expression
[144]
Rat Experimental periodontitis 25, 100, 500 nmol intragingival injections 1 h before periodontitis
induction, and thereafter, daily for 11 days.
Periodontium
;; alveolar bone loss
(100 nmol)
; MPO activity
; MMP-1, ; MMP-8
; iNOS
; NF-jB
;; IL-1b (100 nmol)
; TNF-a
;; malondialdehyde
(100 nmol)
" GSH (100 nmol)
"" bone alkaline phosphatase
(100 nmol)
[145]
Human
keratino-
cytes
Psoriasis 14-day 1% GSNO ointment Biopsy of psoriatic lesion
; IP-10, MCP-1, RANTES
- IL-8
; ICAM-1
; CD14+ and CD3+ inﬁltration
Keratinocytes primary cell
culture
; IP-10
;; MACP-1, RANTES
- IL-8
; ICAM-1 and sICAM-1
[29]
Symbols used: ":‘‘increase of’’; ;:‘‘decrease of’’; "":‘‘increaseP 100%’’; ;;:‘‘decreaseP 50%’’; -:‘‘no effects on’’.
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S-glutathionylation, i.e. the reversible formation of protein-
glutathione mixed disulﬁdes, has been demonstrated to result
from GSNO exposure [130]. It has been suggested that such
modiﬁcation could arise either from a direct reaction between
reduced proteins and GSNO or as a result of denitrosylation of
S-nitrosylated proteins by reduced GSH [131]. Some proteins seemto be preferentially glutathionylated by GSNO, with the preference
for S-nitrosylation or S-thiolation possibly deriving from tuning of
reaction kinetics by the thiol environment [1]. Trascriptional fac-
tors such as the AP-1 component Jun and NF-jB monomer p50
[132,133] or regulatory proteins S100A8 and S100A9 [134] were
suggested to undergo S-glutathionylation on conserved cysteine
residues upon GSNO exposure. Nevertheless the question of
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sothiol formation or exposure has not yet been conclusively
addressed [1].Other regulatory mechanism
Finally, other studies have demonstrated the occurrence of
GSNO effects based on more canonical, NO-related mechanisms
[1]. Classical cGMP-dependent effects were observed in PBMCs
[36,41], rodent ﬁbroblast and epithelial cell lines [110], as well as
in mouse BV-2 microglial cells [74]. The role of cGMP-dependent
protein kinase (PKG) in the activation of NF-jB by direct phosphor-
ylation of p65 or IjB [36] or in the activation of CREB [74] has been
proposed.
It is worth noting that pathways potentially modulated by GSNO
may be differentially activated depending on GSNO decay, cell type,
and cell activation status. Some target proteins may be preferen-
tially activated by speciﬁc modiﬁcations (S-nitrosylation or
S-thiolation), and the susceptibility of themodiﬁed proteins to den-
itrosylation and deglutathionylation reactionsmay also be different
[135]. A recent study identiﬁed sites thatwould be preferably trans-
nitrosylated by GSNO [136]. The opposing effects of GSNO reported
in the literature are thus not necessarily conﬂicting, being highly
context dependent. The following examples are rather clear in this
perspective: (a) different kinetics of GSNO decomposition may
increase or decrease IL-8 expression through p38 or ERK1/2 and
NF-jB pathways, respectively [37]; (b) the cGMP-dependent sig-
naling system is not efﬁcient in the U937 cell line and, conse-
quently, the redox-sensitive pathways may be expected to prevail
in these cells [30]; (c) upregulation of protective mechanisms in
response to non-lethal GSNO concentrations, LPS or cytokine pre-
stimulationmay redirect the ability of a subsequent GSNO exposure
to upregulate p53 and to initiate macrophage apoptosis [75]. These
mechanisms may explain, at least in part, the reported ability of
GSNO to act in both a pro- and anti-inﬂammatory manner.
Further factors undergoing to modulation by GSNO or other
S-nitrosothiols and NO-donors were reported in recent reviews
(e.g. [6,12,15]). The present overview refers to studies focused on
cytokine expression by exogenously added GSNO, and shows that
such treatment may modulate multiple molecular targets involved
in gene transcription ranging from transcription factors to
upstream signaling cascades, mRNA stability and translation
(Fig. 2). The large number of factors involved accounts for the
growing number of genes regulated by GSNO treatments. Notably
all mammalian iNOS genes exhibit homologies to binding sites for
numerous transcription factors including AP-1, CREB, HIF, NF-jB,
NF-IL6, Oct-1, Sp1 and STAT-1a [16], i.e. targets modulated by
GSNO. The latter is thus supposed to exert a feedback regulation
on the very NO production [104].In vivo studies
To date, there have been nearly ten in vivo studies on animal
models dealing with the effects of GSNO on inﬂammation; Table 2
reports a summary of the results obtained. Most investigations
were concerned with neurological injury [45,137–142]. Other
studies have described immunological derangements [105,143]
or induction of inﬂammation in the intestine [144], periodontium
[145] or uvea [143].
Despite the multiplicity of pathological contexts considered and
the differences in routes of administration and doses, these studies
collectively reported beneﬁcial effects of GSNO treatment on dis-
ease symptoms and modulation of inﬂammation. GSNO adminis-
tration was in fact associated with: (i) lower cell inﬁltration in
the diseased tissue; (ii) lower activation of resident macrophages;
(iii) lower expression of adhesion molecules (i.e. ICAM-1,VCAM-1); (iv) lower expression of matrix metalloproteases
(MMP-1, MMP-8, MMP-9); (v) lower degrees of apoptosis (via
inhibition of caspase 3); (vi) lower iNOS activity; (vii) decreased
oxidative stress markers (mieloperoxidase activity, peroxynitrite,
oxidized lipids and proteins). Regarding in particular the expres-
sion of cytokines, this aspect was taken into account by ﬁve
studies. These latter [105,138,143–145] conﬁrmed that NF-jB
activation is reduced, as showed in in vitro studies, and also
reported a decreased expression of the pro-inﬂammatory cytokines
TNFa, IL-1b, IFN-c and IL-13. IL-10 was also shown to be lowered
by GSNO treatment [143]. On the other hand, Olson et al. [105]
obtained different results in a study on allergic airway inﬂamma-
tion, showing that in vivo instillation of GSNO did not change sig-
niﬁcantly markers of inﬂammation or mucus metaplasia, even if
NF-jB and HIF-1 activation were reduced. Authors concluded that
the discrepancy might be due to the involvement of other not-
investigated signalling pathway, in addition to NF-jB and HIF-1,
and/or to C57BL/6 mice being less sensitive to NF-jB activity.
Interestingly, GSNO-dependent reduction of inﬂammation
response in the periodontitis model [145] was observed with the
lowest GSNO doses (25 and 100 mmol), while the intragingival
injection of 500 mmol was not associated with reduction of neither
inﬂammation (IL-1b, TNFa) nor oxidative stress markers (malondi-
aldehyde, GSH). These ﬁndings conﬁrm the bimodality of biological
action of NO and NO-compounds, pointing out that likely a concen-
tration threshold, affecting the control of inﬂammation, likely
exists.
In humans, several clinical trials investigated the therapeutic
efﬁcacy of GSNO, but they have been mainly focused on GSNO
effects on platelet aggregation, vasodilation and bronchodilation
[1,146]. A small study conducted on three healthy human subjects
and three psoriatic patients showed that a 14-day skin treatment
with an ointment containing GSNO reduced the expression of che-
mokines as well as of adhesion molecules (Table 2) that promote
the inﬂammatory inﬁltrate during psoriasis [29].
The cited studies did not deepen in exploring the effect of
in vivo endogenous NO production on cytokine expression. Anyway
studies on mice knock-out for the iNOS gene conﬁrmed that
endogenous NO modulate the expression of IL-1b [38,39].
Altogether, in vivo studies suggests that GSNO could be a
promising therapeutic agent in several diseases, but further work
is necessary to detail the mechanisms by which GSNO regulates
inﬂammatory cells, endothelium, smooth muscle cells as well as
platelets, and to identify the best application routes and doses to
the scope.
Concluding remarks
GSNO plays an immunoregulatory role in the induction and
inhibition of inﬂammatory cytokines. The effects of exogenous
GSNO in vitro appears to be determined by several factors ranging
from the cell type to the variables associated with incubations,
with possible consequences on the route and kinetics of GSNO
decay and on the reactions produced. The biological consequences
of these reactions are diverse and not fully predictable, neverthe-
less, basing on data from in vivo models, anti-inﬂammatory
properties of GSNO seem to prevail on pro-inﬂammatory ones.
Again the responsivity of the animal model, the concentration
and/or the route of GSNO administration used may signiﬁcantly
affect the ﬁnal outcome. The many variables that can affect GSNO
activity, and the ﬁnding that most of its biological functions are
related to transnitrosylation reactions, may thus justify the design
of novel GSNO-based derivatives for therapeutic use [147]. Further
studies are however required for a full comprehension of all factors
involved, and to ascertain the feasibility of GSNO-based pharmaco-
logical treatments for speciﬁc disease conditions.
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